Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Malassezia furfur is a lipophilic yeast that naturally colonizes human skin and body surfaces, thriving in lipid-rich environments through secretion of lipases like MfLIP1 to break down external lipids for growth. It reproduces via unipolar budding from bottle-shaped phialides, forming globose to ellipsoidal yeast cells, and exhibits variable colony morphology from creamy yellow to brown. As a commensal, it maintains skin homeostasis by influencing barrier function and immunity, but overgrowth or imbalance triggers diseases such as seborrheic dermatitis, pityriasis versicolor, atopic eczema, and folliculitis, particularly in immunocompromised individuals. The secreted aspartyl protease Mfsap1 promotes fungal adhesion, dispersal, and inflammation in barrier-compromised skin. Antifungals like azoles target it by disrupting ergosterol synthesis in the cell membrane, though resistance and irritation pose challenges; synergistic plant extracts show promise in reducing fungal load and inflammation. Deep-seated infections occur rarely in vulnerable patients.
Inhibition of ergosterol synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Malassezia furfur (null).